/RNA
RNA Stock - Avidity Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$72.34+0.28%
+$0.20 (+0.28%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).49
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-0.5%upside
Target: $71.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RNA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$71.62 – $73.06
TARGET (TP)$72.00
STOP LOSS$66.55
RISK/REWARD1:-0.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$72.61
52W Low$21.51
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $10.90M | $9.56M | $9.22M | $9.33M | $6.79M |
| Gross Profit | $10.90M | $7.46M | $7.84M | $-91,856,000 | $-30,815,000 |
| Gross Margin | 100.0% | 78.0% | 85.0% | -984.9% | -454.0% |
| Operating Income | $-378,936,000 | $-235,598,000 | $-178,913,000 | $-118,051,000 | $-44,277,000 |
| Net Income | $-322,302,000 | $-212,220,000 | $-173,995,000 | $-118,009,000 | $-44,355,000 |
| Net Margin | -2957.7% | -2219.9% | -1886.3% | -1265.4% | -653.5% |
| EPS | $-2.89 | $-2.91 | $-3.34 | $-2.85 | $-2.05 |
Company Overview
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
2
13%
Buy / Outperform
13
87%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
15 Bullish0 Neutral/Bearish
Price Targets
$53
Average Target
↓ 26.4% Downside
Now
$20
Low
$53
Average
$72
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 17th 2025 | Roth Capital | Initiation | Buy | $62 |
| July 10th 2025 | Goldman | Resumed | Buy | $55 |
| June 24th 2025 | Bernstein | Initiation | Outperform | $50 |
| June 17th 2025 | Wolfe Research | Initiation | Outperform | $55 |
| June 11th 2025 | Raymond James | Initiation | Strong Buy | $65 |
| March 13th 2025 | Citigroup | Initiation | Buy | $70 |
| March 12th 2025 | BMO Capital Markets | Initiation | Outperform | $72 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $70 |
| December 20th 2024 | H.C. Wainwright | Initiation | Buy | $72 |
| November 26th 2024 | RBC Capital Mkts | Initiation | Outperform | $67 |
| September 24th 2024 | Goldman | Initiation | Buy | $59 |
| August 28th 2024 | Barclays | Initiation | Overweight | $63 |
| May 3rd 2024 | BofA Securities | Initiation | Buy | $40 |
| March 14th 2024 | Cantor Fitzgerald | Initiation | Overweight | $60 |
| May 22nd 2023 | Evercore ISI | Upgrade | Outperform | $20 |
Earnings History & Surprises
RNABeat Rate
50%
Last 18 quarters
Avg Surprise
-1.5%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-1.27
Q4 2025
EPS Surprise History
Q1 24
-46.3%
$-0.79vs$-0.54
Q2 24
+2.5%
$-0.79vs$-0.81
Q3 24
+14.5%
$-0.65vs$-0.76
Q4 24
+8.5%
$-0.65vs$-0.71
Q1 25
-5.3%
$-0.80vs$-0.76
Q2 25
-2.3%
$-0.90vs$-0.88
Q3 25
-27.4%
$-1.21vs$-0.95
Q4 25
-16.5%
$-1.27vs$-1.09
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.11 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-1.09 | $-1.27 | -16.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.95 | $-1.21 | -27.4% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.88 | $-0.90 | -2.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.76 | $-0.80 | -5.3% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.71 | $-0.65 | +8.5% | ✓ BEAT |
Q3 2024 | Aug 9, 2024 | $-0.76 | $-0.65 | +14.5% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.81 | $-0.79 | +2.5% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.54 | $-0.79 | -46.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.76 | $-0.71 | +6.6% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.84 | $-0.66 | +21.4% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.90 | $-0.74 | +17.8% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.84 | $-0.88 | -4.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.97 | $-0.82 | +15.5% | ✓ BEAT |
Q3 2022 | Aug 9, 2022 | $-0.74 | $-0.92 | -24.3% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.94 | $-0.71 | +24.5% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-0.73 | $-0.82 | -12.3% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.63 | $-0.68 | -7.9% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.77 | $-0.70 | +9.1% | ✓ BEAT |
Latest News
Avidity Biosciences Announces MAP For Investigational Therapy Delpacibart Zotadirsen For Eligible People With Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping In US
📈 PositiveBenzinga•Nov 19, 2025, 02:15 PM
Chardan Capital Maintains Neutral on Avidity Biosciences, Maintains $72 Price Target
➖ NeutralBenzinga•Nov 11, 2025, 12:59 PM
Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 09:24 PM
TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74
📉 NegativeBenzinga•Oct 29, 2025, 01:03 PM
Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
📉 NegativeBenzinga•Oct 28, 2025, 11:16 AM
RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72
➖ NeutralBenzinga•Oct 28, 2025, 10:18 AM
Dyne Therapeutics shares are trading higher after Novartis announced the acquisition of Avidity Biosciences, which also develops therapies for neuromuscular disease.
📈 PositiveBenzinga•Oct 27, 2025, 04:48 PM•Also: ,
Citigroup Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
📉 NegativeBenzinga•Oct 27, 2025, 04:43 PM•Also:
Raymond James Downgrades Avidity Biosciences to Market Perform
📉 NegativeBenzinga•Oct 27, 2025, 03:22 PM
Avidity Biosciences shares are trading higher after Novartis announced it will acquire the company for $72 per share in cash.
📈 PositiveBenzinga•Oct 27, 2025, 01:43 PM•Also:
Bernstein Downgrades Avidity Biosciences to Market Perform, Raises Price Target to $72
➖ NeutralBenzinga•Oct 27, 2025, 11:39 AM
Needham Downgrades Avidity Biosciences to Hold, Maintains Price Target to $65
➖ NeutralBenzinga•Oct 27, 2025, 11:29 AM
HC Wainwright & Co. Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
➖ NeutralBenzinga•Oct 27, 2025, 10:44 AM
Avidity stock surges on $12B Novartis deal
📈 PositiveSeeking Alpha•Oct 27, 2025, 08:35 AM•Also:
Reported Sunday, Novartis Agrees To Acquire Avidity Biosciences For $12B To Strengthen Late-Stage Neuroscience Pipeline And Expand RNA Therapeutics Portfolio
📈 PositiveBenzinga•Oct 27, 2025, 06:36 AM•Also:
Novartis On Sunday Announced The Acquisition Of Avidity Biosciences For $72/Share In Cash
📈 PositiveBenzinga•Oct 26, 2025, 07:24 PM•Also:
Avidity Biosciences Announces Pre-BLA Meeting With FDA For del-zota In DMD44p; Submission Planned For Q1 2026
📈 PositiveBenzinga•Oct 13, 2025, 01:06 PM
Avidity Biosciences To Present Phase 1/2 Data On Delpacibart Zotadirsen For Duchenne Muscular Dystrophy At 2025 World Muscle Society Congress
➖ NeutralBenzinga•Oct 6, 2025, 01:06 PM
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $65
➖ NeutralBenzinga•Sep 22, 2025, 03:10 PM
Roth Capital Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $62
📈 PositiveBenzinga•Sep 17, 2025, 02:18 PM
Frequently Asked Questions about RNA
What is RNA's current stock price?
Avidity Biosciences, Inc. (RNA) is currently trading at $72.34 per share. The stock has moved +0.28% today.
What is the analyst price target for RNA?
The average analyst price target for RNA is $72.00, based on 1 analyst.
What sector is Avidity Biosciences, Inc. in?
Avidity Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RNA's market cap?
Avidity Biosciences, Inc. has a market capitalization of $9.49 billion, making it a mid-cap company.
Does RNA pay dividends?
No, Avidity Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$114.94
Mkt Cap: $7.5B
CAI
Caris Life Sciences, Inc.
$27.94
Mkt Cap: $7.9B
CYTK
Cytokinetics, Incorporated
$62.72
Mkt Cap: $7.5B
JAZZ
Jazz Pharmaceuticals plc
$166.99
Mkt Cap: $10.1B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
MRUS
Merus N.V.
$97.01
Mkt Cap: $7.4B
NUVL
Nuvalent, Inc.
$103.80
Mkt Cap: $7.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$112.14
Mkt Cap: $7.5B
TECH
Bio-Techne Corporation
$58.27
Mkt Cap: $9.1B
Explore stocks similar to RNA for comparison